Misoprostol is a synthetic prostaglandin E1 analog that was developed in the 1970s and approved for medical use in the 1980s. Its history is notable for its initial role in the prevention and treatment of NSAID-induced gastric ulcers, as it helps reduce gastric acid secretion and protect the stomach lining. Over time, its clinical use expanded significantly due to its ability to stimulate uterine contractions and promote cervical ripening, making it an important drug in obstetric and gynecological practice, including medical management of miscarriage and induction of labor. However, its potent uterotonic effects also led to strict medical supervision and regulatory controls in many settings.
BRAND NAMES
Cytotec (most widely known international brand)
Cytolog
Misoprost
Cytotec-GE (generic equivalents in some regions)
Gymiso (commonly used in some European countries in combination products)
MECHANISM OF ACTION
Misoprostol is a prostaglandin E1 (PGE1) analog that binds to prostaglandin receptors on gastric parietal cells and uterine smooth muscle. In the stomach, it inhibits gastric acid secretion and increases mucus and bicarbonate production, providing a protective effect on the gastric mucosa. In the uterus, it stimulates strong uterine contractions and promotes cervical softening and dilation, making it useful in obstetric and gynecological procedures.
PHARMACOKINETICS
Absorption
Misoprostol is rapidly absorbed after oral or vaginal administration and is quickly converted to its active metabolite, misoprostol acid. Peak levels occur within about 30 minutes (oral) and are delayed with vaginal use.
Distribution
Misoprostol, the volume of distribution (Vd) is relatively small to moderate and is mainly described for its active metabolite, misoprostol acid. It is approximately 0.2–0.3 L/kg (about 14–21 L in a 70 kg adult), indicating that the drug is largely confined to the extracellular fluid with limited extensive tissue binding.
Metabolism
It is extensively metabolized in the liver to misoprostol acid, the biologically active form responsible for its effects.
Elimination
Excretion occurs mainly through the kidneys as inactive metabolites. The drug has a short half-life (about 20–40 minutes).
PHARMACODYNAMICS
Misoprostol reduces gastric acid secretion by inhibiting adenylate cyclase activity in parietal cells and increases mucosal protection. In the uterus, it increases intracellular calcium levels in smooth muscle, leading to powerful uterine contractions and cervical ripening, which is why it is widely used in labor induction and medical termination protocols under supervision.
ADMINISTRATION
Misoprostol can be given orally, sublingually, buccally, or vaginally, depending on indication. It is used for gastric ulcer prevention, medical management of miscarriage, induction of labor, and postpartum hemorrhage control. Route of administration influences onset and intensity of effect.
DOSAGE AND STRENGTH
Misoprostol is available in tablet form, most commonly in strengths of 100 micrograms (mcg) and 200 mcg. The dosage varies significantly depending on the clinical indication. For prevention of NSAID-induced gastric ulcers, it is typically given at 200 mcg four times daily, with a possible reduction to 100 mcg four times daily if not tolerated.
DRUG INTERACTIONS
Misoprostol has few significant drug interactions, but concurrent use with antacids containing magnesium may increase diarrhea risk. It may also have additive uterotonic effects when combined with other prostaglandins or oxytocic agents.
FOOD INTERACTIONS
Food does not significantly affect absorption, but taking it with meals may reduce gastrointestinal side effects such as diarrhea and abdominal cramps.
CONTRAINDICATIONS
Misoprostol is contraindicated in pregnancy when used for gastric ulcer prevention, as it may cause uterine contractions and fetal harm. It should not be used in individuals with known hypersensitivity to prostaglandins.
SIDE EFFECTS
Diarrhea (most common)
Abdominal cramping
Nausea and vomiting
Headache
Fever or chills
Uterine cramps (when used in obstetric doses)
Vaginal bleeding (in gynecological use)
OVER DOSAGE
Overdose of Misoprostol is primarily characterized by exaggerated pharmacological effects, especially involving the gastrointestinal and uterine systems. Common manifestations include severe abdominal pain, intense diarrhea, nausea, vomiting, and dehydration due to excessive stimulation of intestinal smooth muscle and secretions.
TOXICITY
Toxicity of Misoprostol is mainly an extension of its prostaglandin-mediated effects on the gastrointestinal tract and uterus. In cases of excessive exposure, it can cause severe and persistent diarrhea, abdominal cramping, nausea, vomiting, and significant fluid and electrolyte loss leading to dehydration.
